Kadmon Holdings, Inc. (KDMN)

Nov 9, 2021 - KDMN was delisted (reason: acquired by Sanofi)
9.50
0.00 (0.00%)
At close: Nov 8, 2021 12:00 AM
9.49
-0.01 (-0.11%)
After-hours:Nov 8, 2021 7:17 PM EST
Market Cap1.70B
Revenue (ttm)16.08M
Net Income (ttm)-122.41M
Shares Out178.52M
EPS (ttm)-0.71
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,424,582
Open9.49
Previous Close9.50
Day's Range9.48 - 9.50
52-Week Range3.45 - 9.50
Beta1.12
AnalystsStrong Buy
Price Target12.10 (+27.4%)
Earnings DateNov 4, 2021

About KDMN

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD...

IndustryBiotechnology
IPO DateJul 27, 2016
Employees127
Stock ExchangeNASDAQ
Ticker SymbolKDMN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for KDMN stock is "Strong Buy." The 12-month stock price forecast is 12.10, which is an increase of 27.37% from the latest price.

Price Target
$12.10
(27.37% upside)
Analyst Consensus: Strong Buy

News

Sanofi completes acquisition of Kadmon

Sanofi completes acquisition of Kadmon

Other symbols:SNY
2 months ago - GlobeNewsWire

Kadmon Holdings, Inc. (KDMN) Reports Q3 Loss, Tops Revenue Estimates

Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and 3393.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Thir...

2 months ago - Accesswire

3 Biotech Stocks That Surged in September

Find out why last month was a big one for these three drugmakers.

Other symbols:BLULPTX
3 months ago - The Motley Fool

Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting

NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion prote...

3 months ago - Accesswire

SHAREHOLDER ALERT: WeissLaw LLP Reminds CXP, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations

NEW YORK, Sept. 30, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights o...

Other symbols:ECHO
3 months ago - PRNewsWire

3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health

Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.

Other symbols:BNTXGSKNVOPFESNY
3 months ago - Zacks Investment Research

KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequ...

NEW ORLEANS, Sept. 21, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

Other symbols:SNY
3 months ago - PRNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTS, HRC, JMP, KDMN, FIBK; Shareholders are Encouraged to Co...

NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Triple-S Management Corporation (NYSE: GTS)  concerni...

Other symbols:FIBKGTS
3 months ago - PRNewsWire

SHAREHOLDER ALERT: WeissLaw LLP Reminds ECHO, KDMN, HRC, and DVCR Shareholders About Its Ongoing Investigations

NEW YORK, Sept. 17, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights o...

Other symbols:DVCRECHO
3 months ago - PRNewsWire

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kadmon Holdings, Inc. - KDMN

NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Actio...

4 months ago - PRNewsWire

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kadmon Holdings, Inc. (NASDAQ: KDMN) and its board of directors concerning the proposed ac...

Other symbols:SNY
4 months ago - PRNewsWire

Kadmon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kadmon Holdings, Inc. ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kadmon Holdings, Inc. (NASDAQ: KDMN) to Sanofi for $9.50 per share in cash is fair to...

4 months ago - Business Wire

Shareholder Alert: Ademi LLP investigates whether Kadmon Holdings, Inc. has obtained a Fair Price in its transaction ...

MILWAUKEE, Sept. 8, 2021 /PRNewswire/ -- Ademi LLP is investigating Kadmon (NASDAQ:KDMN), for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.

4 months ago - PRNewsWire

Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.

Other symbols:SNY
4 months ago - Zacks Investment Research

KDMN Stock: 6 Things to Know About Biopharma Kadmon Holdings as Shares Skyrocket

Kadmon Holdings (KDMN) stock is rising higher on Wednesday following news of a deal with Sanofi (SNY) that comes to $1.9 billion. The post KDMN Stock: 6 Things to Know About Biopharma Kadmon Holdings as...

4 months ago - InvestorPlace

Why Kadmon Holdings Stock Is Rocketing Higher Today

Sanofi adds another bolt-on acquisition in what is turning out to be a busy year for the French pharma titan.

4 months ago - The Motley Fool

Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know

Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another billion-dollar deal. Sanofi-Kadmon Deal Terms: Sanofi an...

Other symbols:SNY
4 months ago - Benzinga

Sanofi to acquire U.S. biopharmaceutical group Kadmon in $1.9 billion deal

French pharmaceutical major Sanofi SA said Wednesday that it has entered into a definitive agreement to acquire U.S.-based biopharmaceutical company Kadmon Holdings Inc.

Other symbols:SNY
4 months ago - Market Watch

France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 billion deal

French drugmaker Sanofi SA has agreed to buy U.S. biopharmaceutical company Kadmon Holdings Inc in a $1.9 billion deal, the companies said on Wednesday.

Other symbols:SNY
4 months ago - Reuters

Sanofi To Acquire Kadmon To Further Strengthen Growth of Transplant Business

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two pr...

4 months ago - Accesswire

Kadmon Announces U.S. Availability of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Ver...

NEW YORK, NY / ACCESSWIRE / August 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets is now commercially available for shipment t...

4 months ago - Accesswire

5 Penny Stocks Analysts Say To Buy With Targets Up To 300%

Penny stocks to buy according to analysts with price targets up to 300% right now. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 300% appeared first on Penny Stocks to Buy, Picks, News ...

Other symbols:SBSENSVERBXBIO
4 months ago - PennyStocks

Implied Volatility Surging for Kadmon Holdings (KDMN) Stock Options

Investors need to pay close attention to Kadmon Holdings (KDMN) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Kadmon Holdings, Inc. (KDMN) Reports Q2 Loss, Lags Revenue Estimates

Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and -42.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research